Efficacy of decitabine combined with low dose chemotherapy on children with acute myeloid leukemia.
10.3760/cma.j.cn112140-20230417-00280
- Author:
Li Yan FAN
1
;
Li GAO
1
;
Di Xin HU
1
;
Jing LING
1
;
Pei Fang XIAO
1
;
Hai Long HE
1
;
Yi WANG
1
;
Jie LI
1
;
Jun LU
1
;
Jian PAN
2
;
Shao Yan HU
1
Author Information
1. Department of Hematology, Children's Hospital of Soochow University, Suzhou 215000, China.
2. Clinical Research Institute of Pediatrics, Soochow University, Suzhou 215000, China.
- Publication Type:Journal Article
- MeSH:
Female;
Male;
Humans;
Child;
Decitabine;
Retrospective Studies;
Leukemia, Myeloid, Acute/drug therapy*;
Drug-Related Side Effects and Adverse Reactions;
Hematopoietic Stem Cell Transplantation
- From:
Chinese Journal of Pediatrics
2023;61(6):550-555
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy of decitabine combined with low dose chemotherapy (LDC) in the treatment of high-risk, refractory and relapsed pediatric acute myeloid leukemia (AML). Methods: Clinical data of 19 AML children treated with decitabine combined with LDC in the Department of Hematology, Children's Hospital of Soochow University from April 2017 to November 2019 were analyzed retrospectively. The therapeutic response, adverse effects and survival status were analyzed,and the outcomes of patients were followed up. Results: Among 19 AML cases, there were 10 males and 9 females. Five cases were high-risk AML, 7 cases were refractory AML, and 7 cases were relapsed AML. After one course of decitabine+LDC treatment, 15 cases achieved complete remission, 3 cases got partial remission, and only 1 case didn't get remission. All patients received allogeneic hematopoietic stem cell transplantation as consolidation therapy. The follow-up time of all cases was 46 (37, 58) months, 14 children had survived. The cumulative three-year overall survival rate was (79±9) %, events free survival rates was (68±11) %, and recurrence free survival rate was (81±10) %. The most common adverse effects related to the induction treatment were cytopenia (19 cases) and infection (16 cases).There were no treatment-related death during the therapy. Conclusion: Decitabine combined with LDC is a safe and effective option for high-risk, refractory and relapsed AML children, which provides an opportunity for HSCT.
